Dr. Michael Binks, M.D., is Vice President & Head of Clinical and Translational Research in the Rare Disease Research Unit (RDRU) at Pfizer. Dr. Binks qualified in medicine at University College London (UCL), UK before training in internal medicine, gastroenterology, neurology, respiratory, emergency medicine, immunology and has specialist accreditation in rheumatology with 14 years in full time clinical and research practice.
Prior to joining Pfizer, Dr. Binks was the Head of Translational Medicine at GlaxoSmithKline for 14 years in the Immuno-Inflammation Therapy Area where he established the Immuno-Epigenetics Drug Discovery Department. In his role, Dr. Binks directed the scientific, clinical and business strategies for the translation of novel target classes in epigenetics, and JAK inhibitors. Dr. Binks brings 22-years of experience translating multiple pre-clinical programs through clinical development, including small molecules, biotherapeutics and Pfizer’s Duchenne Muscular Dystrophy gene therapy program. He is the author of over 50 peer reviewed publications and 2 patents.
As the Vice President & Head of Rare Disease Clinical and Translational Research, Dr. Binks is responsible for leading a team of MDs, MD/PhDs, non-MD clinicians, translational scientists and project leaders that are responsible for translational and clinical development plans, study design and medical oversight for rare hematology, neurology, cardiorenal and endocrine/metabolic diseases.